文章：

治疗对酪氨酸激酶抑制剂治疗不耐受的慢性髓性白血病患者

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy

原文发布日期：2012-10-19

DOI: 10.1038/bcj.2012.30

类型: Original Article

开放获取: 是

英文摘要：

The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR–ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-α, and most adverse events (AEs) observed with front-line and second-line TKI treatment are managed with supportive care. However, some patients are intolerant to TKI therapy and experience AEs that cannot be managed through dose reduction or symptomatic treatment. Careful management of AEs helps patients to remain adherent with treatment and increases their chances for successful outcomes. Proactive vigilance for potential AEs and treatment strategies that reduce symptom burden will help to minimize patient intolerance. This review discusses the most common AEs associated with intolerance to TKI therapy and treatment strategies to help manage patients at risk for or experiencing these events.

摘要翻译： 

过去十年间，随着BCR–ABL1酪氨酸激酶抑制剂（TKIs）的研发与应用，慢性髓系白血病患者的预后得到显著改善。与既往标准治疗方案干扰素-α相比，TKI疗法具有更优的安全性特征，且一线和二线TKI治疗中出现的大多数不良事件可通过支持性治疗得以控制。然而，部分患者对TKI治疗不耐受，其出现的不良事件无法通过剂量调整或对症治疗有效缓解。对不良事件进行精细管理有助于患者维持治疗依从性，并增加获得成功结局的机会。主动警惕潜在不良事件并采取减轻症状负担的治疗策略，将有助于最大限度降低患者不耐受发生率。本综述讨论了与TKI治疗不耐受相关的最常见不良事件，并针对存在相关风险或正经历这些事件的患者提出了治疗管理策略。

原文链接：

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy